In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, IOL Chemicals and Pharmaceuticals has informed that the European Directorate for the Quality of Medicines & Health Care (EDQM) has granted a Certificate of Suitability for Company’s API product ‘MINOXIDIL’ on 4th December 2025. Minoxidil is primarily used as a topical treatment for hereditary hair loss.
The above information is a part of company’s filings submitted to BSE.